Safety Information

KEYTRUDA® (pembrolizumab) Pooled Safety

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Always refer to the full Summary of Product Characteristics before prescribing for up-to-date and complete safety considerations to help minimise the risks associated with the use of KEYTRUDA.

Please click here for the Great Britain Summary of Product Characteristics [External link]
Please click here for the Northern Ireland Summary of Product Characteristics [External link]

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-02188 | Date of Preparation: August 2022